929000-58-8

Basic information

• Product Name: 1-(2-Bromophenylsulfonyl)pyrrolidine
• Synonyms: 1-(2-Bromophenylsulfonyl)pyrrolidine;1-[(2-Bromophenyl)sulphonyl]pyrrolidine98%
• CAS NO: 929000-58-8
• Molecular Formula: C₁₀H₁₂BrNO₂S
• Molecular Weight: 290.19
• Product Categories: blocks;Bromides;Sulfonamides
• Mol File: 929000-58-8.mol
• Article Data: 3

Chemical Properties

• Boiling Point: 393.4±44.0 °C(Predicted)
• Appearance: /
• Density: 1.583±0.06 g/cm3(Predicted)
• Storage Temp.: 2-8°C
• PKA: -5.61±0.20(Predicted)
• CAS DataBase Reference: 1-(2-Bromophenylsulfonyl)pyrrolidine(CAS DataBase Reference)
• NIST Chemistry Reference: 1-(2-Bromophenylsulfonyl)pyrrolidine(929000-58-8)
• EPA Substance Registry System: 1-(2-Bromophenylsulfonyl)pyrrolidine(929000-58-8)

Safety Data

• Hazardous Substances Data: 929000-58-8(Hazardous Substances Data)

Usage

General Description

1-(2-Bromophenylsulfonyl)pyrrolidine, also known as BPP, is a chemical compound with potential applications in medicinal chemistry and drug development. It is a pyrrolidine derivative that contains a sulfonyl functional group and a bromophenyl substituent. BPP has been studied for its potential as an anti-cancer agent, with research suggesting that it may have inhibitory effects on certain cancer cell lines. Additionally, it has also been investigated for its potential as a therapeutic agent in other diseases, such as neurodegenerative disorders. Further research is needed to fully understand the pharmacological properties and potential uses of 1-(2-Bromophenylsulfonyl)pyrrolidine.

Upstream product

• 108-86-1 bromobenzene 
• 123-75-1 pyrrolidine 
• 2905-25-1 o-bromobenzenesulfonyl chloride 

Downstream Products

• 1202647-58-2 [2'-(Pyrrolidine-1-sulfonyl)-biphenyl-4-ylmethyl]-(tetrahydro-pyran-4-yl)-amine 
• 1202647-57-1 ((S)-2-Methoxy-1-methyl-ethyl)-[2'-(pyrrolidine-1-sulfonyl)-biphenyl-4-ylmethyl]-amine 
• 1322001-00-2 C₂₃H₃₀N₂O₃S 
• 1322001-01-3 N,N-dimethyl-N-((2'-(pyrrolidin-1-ylsulfonyl)biphenyl-4-yl)methyl)ethane-1,2-diamine 
• 1202647-56-0 (3-Methyl-oxetan-3-ylmethyl)-[2'-(pyrrolidine-1-sulfonyl)-biphenyl-4-ylmethyl]-amine 
• 1202647-53-7 4-Methyl-1-[2'-(pyrrolidine-1-sulfonyl)-biphenyl-4-ylmethyl]-piperidin-4-ol 
• 1322001-06-8 C₂₀H₂₇N₃O₂S 
• 1322001-09-1 C₂₀H₂₇N₃O₂S 
• 1322001-35-3 2-methyl-N-((2'-(pyrrolidin-1-ylsulfonyl)biphenyl-4-yl)methyl)propan-1-amine hydrochloride 
• 1322000-97-4 C₂₂H₃₀N₂O₂S 
• 1202647-49-1 2'-(pyrrolidin-1-ylsulfonyl)biphenyl-4-carbaldehyde 
• 1394834-06-0 1-benzenesulfonyl-2,3-dihydro-1H-pyrrole 
• 5033-22-7 1-(phenylsulfonyl)-pyrrolidine 

Relevant articles and documents

AMINO-SUBSTITUTED HETEROCYCLIC DERIVATIVES AS SODIUM CHANNEL INHIBITORS

The present invention relates to novel aminoindazolyl derivative compounds of Formula(I), the use of said compounds in treating diseases mediated by modulation of voltage-gated sodium channels in particular Nav1.7 AND to compositions containing said derivatives.

Design and discovery of a selective small molecule κ opioid antagonist (2-methyl- n -((2′-(pyrrolidin-1-ylsulfonyl)biphenyl-4-yl) methyl)propan-1-amine, PF-4455242)

By use of parallel chemistry coupled with physicochemical property design, a series of selective κ opioid antagonists have been discovered. The parallel chemistry strategy utilized key monomer building blocks to rapidly expand the desired SAR space. The potency and selectivity of the in vitro κ antagonism were confirmed in the tail-flick analgesia model. This model was used to build an exposure-response relationship between the ? Ki and the free brain drug levels. This strategy identified 2-methyl-N-((2′- (pyrrolidin-1-ylsulfonyl)biphenyl-4-yl)methyl)propan-1-amine, PF-4455242, which entered phase 1 clinical testing and has demonstrated target engagement in healthy volunteers.